IP Library Granted Patent US 12,740,947
Granted Patent B2
US 12,740,947 · App. 18/322,111 · Granted Sep 22, 2026

Method of initiating sotalol hydrochloride dosing

Inventors: John Charin Somberg (Chicago, IL); Brandon Ira Kashfian (Chicago, IL); Janos Molnar (Chicago, IL)
Assignee: AltaThera Pharmaceuticals LLC
A61K31/136A61K9/0019A61K9/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,740,947
App. No.
18/322,111
Granted
Sep 22, 2026
Kind
B2
Abstract

This disclosure provides a method of safely and rapidly initiating or escalating oral sotalol therapy by administering an intravenous dosage of sotalol followed by oral sotalol twice daily.

Claims (16)

1 . A method of administering sotalol hydrochloride therapy comprising:

administering to a subject a single intravenous (IV) dosage of sotalol hydrochloride:

in an amount in the range of 99 mg to 128 mg;

over a period of 1 hour; and

at a rate in the range of about 1.65 mg/min to about 2.13 mg/min; wherein in response to the administering of the IV dosage, the subject is capable of achieving a peak serum, plasma or blood concentration of the sotalol hydrochloride in the range of 90-110% of a C max at steady-state expected for that subject from oral dosing; and

administering to the subject at least one 160 mg oral dose of sotalol hydrochloride and wherein the 160 mg oral dose starts at about 2-12 hours after completion of the administering of the IV dosage.

2 . The method of claim 1 , wherein the subject is administered a number of oral doses timed, from each other and/or the IV dose, such that the subject is capable of achieving a peak serum, plasma or blood concentration of sotalol hydrochloride at least three times within 24 hours that is in the range of 90-110% of the expected C max at steady-state for that subject from 160 mg oral dosing.

3 . The method of claim 1 , wherein the subject is naïve to sotalol prior to administering the sotalol hydrochloride therapy.

4 . The method of claim 1 , wherein the administering of the at least one 160 mg oral dose starts at about 4-12 hours after completion of the administering of the IV dosage.

5 . The method of claim 4 , wherein one or more of the at least one 160 mg oral dose is administered at a 12- to 48-hour interval from administration of a previous oral dose.

6 . The method of claim 1 , wherein the administering of the IV dosage begins at a time when the subject has a serum, plasma or blood concentration of sotalol hydrochloride at a steady state C min .

7 . The method of claim 4 , wherein the subject is one who had been administered a 120 mg oral dose of sotalol hydrochloride prior to the administering of the IV dosage.

8 . The method of claim 1 , wherein one or more of the at least 160 mg one oral dose is administered at a 12- to 48-hour interval from administration of a previous oral dose.

9 . The method of claim 1 , wherein the subject has atrial fibrillation or atrial flutter.

10 . The method of claim 2 , wherein the subject has atrial fibrillation or atrial flutter.

11 . The method of claim 1 , wherein the subject is in sinus rhythm prior to initiation of the administering of the IV dosage.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2023
From: SOMBERG, JOHN CHARIN; KASHFIAN, BRANDON IRA; MOLNAR, JANOS
To: ALTATHERA PHARMACEUTICALS LLC
Reel/Frame 066160/0061 →
Continuity (3)
Continuation 16693310 · Nov 24, 2019
Continuation In Part 16103815 · Aug 14, 2018
Related Publication 20230293455A1 · Sep 21, 2023
References Cited (400)
US 6043273A · Duhaylongsod · 2000 [cited by applicant]
US 6060454A · Duhaylongsod · 2000 [cited by applicant]
US 6101412A · Duhaylongsod · 2000 [cited by applicant]
US 6124363A · Appleby et al. · 2000 [cited by applicant]
US 6136327A · Gupta et al. · 2000 [cited by applicant]
US 6281246B2 · Sankaranarayanan · 2001 [cited by applicant]
US 6369114B1 · Weil et al. · 2002 [cited by applicant]
US 6482811B1 · Bacaner et al. · 2002 [cited by applicant]
US 6491039B1 · Dobak, III · 2002 [cited by applicant]
US 6500459B1 · Chhabra et al. · 2002 [cited by applicant]
US 6544981B2 · Stein et al. · 2003 [cited by applicant]
US 6627223B2 · Percel et al. · 2003 [cited by applicant]
US 6632217B2 · Harper et al. · 2003 [cited by applicant]
US 6645524B2 · Midha et al. · 2003 [cited by applicant]
US 6720001B2 · Chen et al. · 2004 [cited by applicant]
US 6800668B1 · Odidi et al. · 2004 [cited by applicant]
US 6899700B2 · Gehling et al. · 2005 [cited by applicant]
US 6916813B2 · Atwal et al. · 2005 [cited by applicant]
US 6944638B1 · Putnam · 2005 [cited by applicant]
US 7004171B2 · Benita et al. · 2006 [cited by applicant]
US 7005425B2 · Belardinelli et al. · 2006 [cited by applicant]
US 7005436B2 · Lloyd et al. · 2006 [cited by applicant]
US 7022343B2 · Philbrook et al. · 2006 [cited by applicant]
US 7048945B2 · Percel et al. · 2006 [cited by applicant]
US 7090830B2 · Hale et al. · 2006 [cited by applicant]
US 7179597B2 · Woosley · 2007 [cited by applicant]
US 7289847B1 · Gill et al. · 2007 [cited by applicant]
US 7341737B2 · Gehling et al. · 2008 [cited by applicant]
US 7371254B2 · Dobak, III · 2008 [cited by applicant]
US 7396524B2 · Yan · 2008 [cited by applicant]
US 7417038B1 · Anker et al. · 2008 [cited by applicant]
US 7526335B2 · Ferek-Petric · 2009 [cited by applicant]
US 7538092B2 · Orlando et al. · 2009 [cited by applicant]
US 7572776B2 · Yu et al. · 2009 [cited by applicant]
US 7674820B2 · Fedida et al. · 2010 [cited by applicant]
US 7745665B2 · Gant et al. · 2010 [cited by applicant]
US 7765110B1 · Koneru · 2010 [cited by applicant]
US 7776844B2 · Yu et al. · 2010 [cited by applicant]
US 7815936B2 · Hasenzahl et al. · 2010 [cited by applicant]
US 7829573B2 · Curwen et al. · 2010 [cited by applicant]
US 7846968B2 · Chien et al. · 2010 [cited by applicant]
US 7885824B1 · Koneru · 2011 [cited by applicant]
US 7885827B1 · Koneru · 2011 [cited by applicant]
US 7951183B2 · Dobak, III · 2011 [cited by applicant]
US 8106099B2 · Brendel et al. · 2012 [cited by applicant]
US 8236782B2 · Mosher et al. · 2012 [cited by applicant]
US 8263125B2 · Vaya et al. · 2012 [cited by applicant]
US 8268352B2 · Vaya et al. · 2012 [cited by applicant]
US 8313757B2 · Lengerich · 2012 [cited by applicant]
US 8377994B2 · Gray et al. · 2013 [cited by applicant]
US 8399018B2 · Lichter et al. · 2013 [cited by applicant]
US 8440168B2 · Yang et al. · 2013 [cited by applicant]
US 8465769B2 · Petereit et al. · 2013 [cited by applicant]
US 8466277B2 · Orlando et al. · 2013 [cited by applicant]
US 8575348B2 · Rao et al. · 2013 [cited by applicant]
US 8696696B2 · Solem · 2014 [cited by applicant]
US 8709076B1 · Matheny et al. · 2014 [cited by applicant]
US 8753674B2 · Helson · 2014 [cited by applicant]
US 8828432B2 · Lengerich · 2014 [cited by applicant]
US 8865213B2 · Sheth et al. · 2014 [cited by applicant]
US 8871452B2 · Lee · 2014 [cited by applicant]
US 8906847B2 · Cleemann et al. · 2014 [cited by applicant]
US 8962574B2 · Reilly · 2015 [cited by applicant]
US 8987262B2 · Leaute-Labreze et al. · 2015 [cited by applicant]
US 9011526B2 · Matheny · 2015 [cited by applicant]
US 9016221B2 · Brennan et al. · 2015 [cited by applicant]
US 9044319B2 · Matheny · 2015 [cited by applicant]
US 9060969B2 · Matheny · 2015 [cited by applicant]
US 9069887B2 · Gupta et al. · 2015 [cited by applicant]
US 9078929B2 · Kuebelbeck et al. · 2015 [cited by applicant]
US 9161952B2 · Matheny et al. · 2015 [cited by applicant]
US 9239333B2 · Snider · 2016 [cited by applicant]
US 9255104B2 · Rao et al. · 2016 [cited by applicant]
US 9308084B2 · Matheny · 2016 [cited by applicant]
US 9399067B2 · Mosher et al. · 2016 [cited by applicant]
US 9474719B2 · Mullen et al. · 2016 [cited by applicant]
US 9498481B2 · Rao et al. · 2016 [cited by applicant]
US 9549912B2 · Milner et al. · 2017 [cited by applicant]
US 9554989B2 · Kaplan et al. · 2017 [cited by applicant]
US 9585851B2 · Yun et al. · 2017 [cited by applicant]
US 9585884B2 · Rao et al. · 2017 [cited by applicant]
US 9597302B1 · Yan et al. · 2017 [cited by applicant]
US 9616026B2 · Singh · 2017 [cited by applicant]
US 9682041B2 · Helson · 2017 [cited by applicant]
US 9724297B2 · Thomas et al. · 2017 [cited by applicant]
US 9770514B2 · Ghebre-Sellassie et al. · 2017 [cited by applicant]
US 9889148B2 · Daemmgen et al. · 2018 [cited by applicant]
US 9995756B2 · Saffitz et al. · 2018 [cited by applicant]
US 10117881B2 · Helson · 2018 [cited by applicant]
US 10238602B2 · Helson et al. · 2019 [cited by applicant]
US 10258691B2 · Helson et al. · 2019 [cited by applicant]
US 10347374B2 · Tribble et al. · 2019 [cited by applicant]
US 10349884B2 · Helson et al. · 2019 [cited by applicant]
US 10357458B2 · Helson · 2019 [cited by applicant]
US 10449193B2 · Helson et al. · 2019 [cited by applicant]
US 10450267B2 · Stancl · 2019 [cited by applicant]
US 10512620B1 · Somberg et al. · 2019 [cited by applicant]
US 10537588B2 · Daemmgen et al. · 2020 [cited by applicant]
US 10603316B2 · Xiong et al. · 2020 [cited by applicant]
US 10617639B2 · Helson · 2020 [cited by applicant]
US 10793519B2 · Somberg et al. · 2020 [cited by applicant]
US 10799138B2 · Ivaturi et al. · 2020 [cited by applicant]
US 10888524B2 · Yenkar et al. · 2021 [cited by applicant]
US 10888552B2 · Rothman · 2021 [cited by applicant]
US 11286235B2 · Somberg et al. · 2022 [cited by applicant]
US 11344518B2 · Somberg · 2022 [cited by applicant]
US 11364213B2 · Somberg · 2022 [cited by applicant]
US 11583216B2 · Ivaturi et al. · 2023 [cited by applicant]
US 11610660B1 · Devlin et al. · 2023 [cited by applicant]
US 11696902B2 · Somberg et al. · 2023 [cited by applicant]
US 11957648B2 · Somberg · 2024 [cited by applicant]
US 12390431B2 · Somberg et al. · 2025 [cited by applicant]
US 12396970B2 · Kashfian et al. · 2025 [cited by applicant]
US 12403109B2 · Somberg et al. · 2025 [cited by applicant]
US 12569183B2 · Ivaturi et al. · 2026 [cited by applicant]
US 20070009564A1 · McClain et al. · 2007 [cited by applicant]
US 20070009654A1 · Watanabe et al. · 2007 [cited by applicant]
US 20120003318A1 · Schuler et al. · 2012 [cited by applicant]
US 20140235631A1 · Bunt et al. · 2014 [cited by applicant]
US 20140276404A1 · Orlowski · 2014 [cited by applicant]
US 20150081010A1 · Matheny · 2015 [cited by applicant]
US 20150210712A1 · Blumberg et al. · 2015 [cited by applicant]
US 20160082159A1 · Orlowski · 2016 [cited by applicant]
US 20160128944A1 · Chawrai et al. · 2016 [cited by applicant]
US 20160228379A1 · Kumar et al. · 2016 [cited by applicant]
US 20160271070A1 · Singh et al. · 2016 [cited by applicant]
US 20160271157A1 · Ahmed et al. · 2016 [cited by applicant]
US 20160303133A1 · Dudley et al. · 2016 [cited by applicant]
US 20160317388A1 · Bhargava et al. · 2016 [cited by applicant]
US 20170049705A1 · Mateescu et al. · 2017 [cited by applicant]
US 20170087105A1 · Yan et al. · 2017 [cited by applicant]
US 20170100387A1 · Arora et al. · 2017 [cited by applicant]
US 20170119627A1 · Bhargava et al. · 2017 [cited by applicant]
US 20170157076A1 · Yacoby-Zeevi et al. · 2017 [cited by applicant]
US 20170231885A1 · Cremers et al. · 2017 [cited by applicant]
US 20170258781A1 · Noujaim et al. · 2017 [cited by applicant]
US 20170296493A1 · Thomas et al. · 2017 [cited by applicant]
US 20170348303A1 · Bosse et al. · 2017 [cited by applicant]
US 20180071390A1 · Patel et al. · 2018 [cited by applicant]
US 20190307343A1 · Ivaturi et al. · 2019 [cited by applicant]
US 20190352257A1 · Somberg et al. · 2019 [cited by applicant]
US 20190380605A1 · Ivaturi et al. · 2019 [cited by applicant]
US 20190388371A1 · Somberg · 2019 [cited by applicant]
US 20190389888A1 · McChesney et al. · 2019 [cited by applicant]
US 20200085771A1 · Somberg et al. · 2020 [cited by applicant]
US 20200093759A1 · Somberg et al. · 2020 [cited by applicant]
US 20200226481A1 · Sim et al. · 2020 [cited by applicant]
US 20200253903A1 · Somberg · 2020 [cited by applicant]
US 20200338027A1 · Somberg · 2020 [cited by applicant]
US 20200383941A1 · Brelidze et al. · 2020 [cited by applicant]
US 20210076959A1 · Ivaturi et al. · 2021 [cited by applicant]
US 20210107867A1 · Somberg et al. · 2021 [cited by applicant]
US 20210283049A1 · Somberg · 2021 [cited by applicant]
US 20210346325A1 · Somberg · 2021 [cited by applicant]
US 20220142954A1 · Somberg · 2022 [cited by applicant]
US 20220241225A1 · Somberg · 2022 [cited by applicant]
US 20220339130A1 · Somberg et al. · 2022 [cited by applicant]
US 20230075398A1 · Devlin et al. · 2023 [cited by applicant]
US 20230172883A1 · Kashfian et al. · 2023 [cited by applicant]
US 20230187049A1 · Devlin et al. · 2023 [cited by applicant]
US 20230225664A1 · Ivaturi et al. · 2023 [cited by applicant]
US 20230225997A1 · Kashfian · 2023 [cited by applicant]
US 20230248674A1 · Kashfian · 2023 [cited by applicant]
US 20230255908A1 · Kashfian · 2023 [cited by applicant]
US 20230255909A1 · Kashfian · 2023 [cited by applicant]
US 20230270940A1 · Devlin et al. · 2023 [cited by applicant]
US 20230285273A1 · Kashfian · 2023 [cited by applicant]
US 20230293426A1 · Kashfian · 2023 [cited by applicant]
US 20230310745A1 · Kashfian · 2023 [cited by applicant]
US 20230372268A1 · Kashfian · 2023 [cited by applicant]
US 20240156758A1 · Somberg · 2024 [cited by applicant]
US 20240261242A1 · Kashfian · 2024 [cited by applicant]
US 20250140361A1 · Kashfian et al. · 2025 [cited by applicant]
US 20250152529A1 · Somberg et al. · 2025 [cited by applicant]
US 20250152530A1 · Somberg et al. · 2025 [cited by applicant]
US 20250213504A1 · Kashfian et al. · 2025 [cited by applicant]
US 20250345297A1 · Kashfian et al. · 2025 [cited by applicant]
US 20260034080A1 · Somberg et al. · 2026 [cited by applicant]
AU 737668B2 · 2001 [cited by applicant]
AU 765269B2 · 2003 [cited by applicant]
AU 2003233653A1 · 2003 [cited by applicant]
AU 2005299693A1 · 2006 [cited by applicant]
AU 2010231494A1 · 2011 [cited by applicant]
AU 2013203252A1 · 2013 [cited by applicant]
AU 2013381856A1 · 2015 [cited by applicant]
AU 2011289176B2 · 2015 [cited by applicant]
AU 2016266020B2 · 2018 [cited by applicant]
AU 2017357916A1 · 2019 [cited by applicant]
AU 2016313439B2 · 2019 [cited by applicant]
AU 2015269699B2 · 2020 [cited by applicant]
EP 0898964A1 · 1999 [cited by applicant]
EP 1027329B1 · 2003 [cited by applicant]
EP 1467705A2 · 2004 [cited by applicant]
EP 1474105A2 · 2004 [cited by applicant]
EP 1605976A1 · 2005 [cited by applicant]
EP 2429291A1 · 2012 [cited by applicant]
EP 1501467B1 · 2012 [cited by applicant]
EP 2238127B1 · 2012 [cited by applicant]
EP 2238128B1 · 2012 [cited by applicant]
EP 2228065B1 · 2012 [cited by applicant]
EP 2797556A1 · 2014 [cited by applicant]
EP 2861254A2 · 2015 [cited by applicant]
EP 3100728A1 · 2016 [cited by applicant]
EP 2999461A4 · 2017 [cited by applicant]
EP 2714011B1 · 2018 [cited by applicant]
EP 1951210B1 · 2018 [cited by applicant]
WO 9921829A1 · 1999 [cited by applicant]
WO 03020240A2 · 2003 [cited by applicant]
WO 03059318A2 · 2003 [cited by applicant]
WO 2004082716A1 · 2004 [cited by applicant]
WO 2007053393A2 · 2007 [cited by applicant]
WO 2010132711A1 · 2010 [cited by applicant]
WO 2012167212A3 · 2013 [cited by applicant]
WO 2013185764A2 · 2013 [cited by applicant]
WO 2014133539A1 · 2014 [cited by applicant]
WO 2014143108A1 · 2014 [cited by applicant]
WO 2014186843A1 · 2014 [cited by applicant]
(Devlin, Jodi) Co-pending U.S. Appl. No. 17/566,840, filed Dec. 31, 2021, Specification, Claims, and Figures. [cited by applicant]
(Devlin, Jodi) Co-pending U.S. Appl. No. 18/107,785, filed Feb. 9, 2023, Specification, Claims, and Figures. [cited by applicant]
(Devlin, Jodi) Co-pending U.S. Appl. No. 18/121,980, filed Mar. 15, 2023, Specification, Claims, and Figures. [cited by applicant]
(Ivaturi, Vijay et al.) U.S. Appl. No. 16/376,706, filed Apr. 5, 2019, Specification, Claims, Figures. [cited by applicant]
(Ivaturi, Vijay et al.) U.S. Appl. No. 16/549,620, filed Aug. 23, 2019, Specification, Claims, Figures and File History as of Dec. 2020, 77 pages (abandoned). [cited by applicant]
(Ivaturi, Vijay et al.) U.S. Appl. No. 17/003,297, filed Aug. 26, 2020, Specification, Claims, Figures. [cited by applicant]
(Ivaturi, Vijay et al.) U.S. Appl. No. 18/156,092, filed Jan. 18, 2023, Specification, Claims, Figures. [cited by applicant]
(Kashfian, Brandon Ira et al.) Co-Pending U.S. Appl. No. 17/892,301, filed Aug. 22, 2022, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/126,561, filed Mar. 27, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/135,467, filed Apr. 17, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/304,196, filed Apr. 20, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/306,660, filed Apr. 25, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/315,790, filed May 11, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/321,220, filed May 22, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/323,337, filed May 24, 2023, Specification and Claims. [cited by applicant]
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/324,703, filed May 26, 2023, Specification and Claims. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/103,815, filed Aug. 14, 2018, Specification, Claims, Figures. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/693,310, filed Nov. 24, 2019, Specification, Claims, Figures. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/693,312, filed Nov. 24, 2019, Specification, Claims, Figures. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/726,361, filed Dec. 24, 2019, Specification, Claims, Figures. [cited by applicant]
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 17/861,226, filed Jul. 10, 2022, Specification, Claims, Figures. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 16/849,099, filed Apr. 15, 2020, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 16/863,567, filed Apr. 30, 2020, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 16/946,941, filed Jul. 13, 2020, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 17/306,490, filed May 3, 2021, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 17/585,190, filed Jan. 26, 2022, Specification and Claims. [cited by applicant]
(Somberg, John) Co-Pending U.S. Appl. No. 17/725,189, filed Apr. 20, 2022, Specification and Claims. [cited by applicant]
U.S. Appl. No. 17/003,297, Final Office Action dated Jul. 27, 2022, 16 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Non-Final Office Action dated Mar. 14, 2022, 14 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Notice of Allowance dated Oct. 18, 2022, 7 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Preliminary Amendment filed Dec. 8, 2020, 9 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Response to Final Office Action dated Sep. 27, 2022, 12 pages. [cited by applicant]
U.S. Appl. No. 17/003,297, Response to Mar. 14, 2022 Non-Final Office Action, dated Jun. 15, 2022, 12 pages. [cited by applicant]
Barbey, J.T. “Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects,” Clinical Pharmacology and Therapeutics vol. 66(1) (1999) 91-99. [cited by applicant]
Batra, Anjan S., et al., “Junctional ectopic tachycardia: Current strategies for diagnosis and management,” Progress in Pediatric Cardiology, 35 (2013) 49-54. [cited by applicant]
Batul, S.A., “Intravenous sotalol: Reintroducing a forgotten agent to the electrophysiology therapeutic arsenal,” J. Atrial Fibrillation vol. 9(3) (Feb.-Mar. 2017) 1-5. [cited by applicant]
Blair, Andrew D., et al., Sotalol kinetics in renal insufficiency, Clin. Pharmacol. Ther., 457-463 (Apr. 1981) (7 pages). [cited by applicant]
Boriani, G. et al., Increase in QT/QTc dispersion after low energy cardioversion of chronic persistent atrial fibrillation. International Journal of Cardiology. 2004; 95, 245-250. [cited by applicant]
Borquez, Alejandro A., et al., “Intravenous Sotalol in the Young, Safe and Effective Treatment With Standardized Protocols,” JACC: Clinical Elecrophysiology, vol. 6, No. 4, Apr. 2020:425-32 (2020). [cited by applicant]
Campbell, T.J., “Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bipass comparison with disopyramide and digoxin in a randomised trial,” BR Heart J. (1985) 54:86-90. [cited by applicant]
Cantillon, D. J. and Amuthan, R. “Atrial Fibrillation”, Cleveland Clinic: Center for Continuing Education, Disease Management: https://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/atrial-fibrill… [cited by applicant]
CHOC Children's, “Junctional Ectopic Tachycardia (JET) Care Guideline for Cardiovascular Intensive Care Unit (CVICU),” Sep. 18, 2019. [cited by applicant]
Cilliers, Antionette M., et al., “Junctional ectopic tachycardia in six paediatric patients,” Heart; 78:413-415 (1997). [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Final Office Action dated Aug. 13, 2019, 13 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Non-Final Office Action dated Feb. 6, 2019, 9 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Notice of Allowance dated Oct. 30, 2019, 12 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Response to Aug. 13, 2019 Final Office Action, filed Oct. 17, 2019, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Response to Dec. 13, 2018 Restriction Requirement, filed Dec. 31, 2018, 3 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Response to Feb. 6, 2019 Non-Final Office Action, filed May 6, 2019, 17 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/103,815, Restriction Requirement dated Dec. 13, 2018, 6 pages. [cited by applicant]
Dumas, M. et al., “Variations of sotalol kinetics in renal insufficiency”, International Journal of Clinical Pharmacology, Therapy, and Toxicology, Oct. 1, 1989, 27(10), Abstract only. [cited by applicant]
El-Assaad, I, “Lone Pediatric Atrial Fibrillation in the United States: Analysis of Over 1500 Cases,” Pediatr. Cardiol. 38:1004-1009, Springer Publishing, United States (2017). [cited by applicant]
FDA Highlights of Prescribing Information sotalol hydrochloride injection (2009), https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022306s000lbl.pdf. [cited by applicant]
FDA Highlights of Prescribing Information Sotylize (sotalol hydrochloride (2014), https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205108s000lbl.pdf. [cited by applicant]
FDA “Highlights of Prescribing Information” for sotalol hydrochloride injection, Revised Mar. 2020, 16 pages, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022306s005lblrpl.pdf. [cited by applicant]
Galloway, C.D., “Development and Validation of a Deep-Learning Model to Screen for Hyperkalemia From the Electrocardiogram,” JAMA Cardiol.: E1-E9, Amer. Med. Assoc., United States (Apr. 3, 2019). [cited by applicant]
Gomes, J.A., “Oral d,l Sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study,” J. Am. Coll. Cardio. 34(2):334… [cited by applicant]
Hannun, A.Y., “Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network,” Nature Medicine 25:65-69, Nature Publishing (Jan. 2019). [cited by applicant]
Ho, D.S.W, et al., “Rapid intravenous infusion of d-l sotalol: time to onset of effects on ventricular refractoriness, and safety,” European Heart J. 16:81-86, European Soc. of Cardiology, UK (1995). [cited by applicant]
Hoffman et al. “Renal Insufficiency and Medication in Nursing Homes” Medicine Deutsches Arzteblatt International 2016; 113: 92-98. [cited by applicant]
Kerin, Nicholas A., “Intravenous Sotalol: an under used treatment strategy,” Cardiology (2018) 140:143-145. [cited by applicant]
Laer, S., et al., “Development of a safe and effective pediatric dosing regimen for sotalol based population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia . . . ” Pediatric Cardiolo… [cited by applicant]
Le Coz, F. et al. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin Pharmacol Ther 1995; 57:533. [cited by applicant]
Learn the Heart, “Antiarrhythmic Drug Review,” https://www.healio.com/cardiology/learn-the-heart/cardiology-review/topic-reviews/antiarrhythmic-drugs (Year: 2022). [cited by applicant]
Li, X, “Efficacy of intravenous sotalol for treatment of incessant tachyarrhythmias in children,” Amer. J. of Cardiology (2017) 119:1366-1370. [cited by applicant]
Li, X., “Pediatric dosing of intravenous sotalol based on body surface area in patients with arrhythmia,” Pediatr Cardiol (2017) 38:1450-1455. [cited by applicant]
Lynch, J.J., et al., “Prevention of ventricular fibrillation by dextrorotatory sotalol in conscious canine model of sudden coronary death,” Amer. Heart J. vol. 109(5) Part 1, (1985) 949-958. [cited by applicant]
Maragnes, P., et al., “Usefulness of oral sotalol for the treatment of junctional ectopic tachycardia,” Int'l J. of Cardiology, 35 (1995) 165-167. [cited by applicant]
Marill, K.A., “Meta-analysis of the risk of torsades de pointes in patients treated with intravenous racemic sotalol,” Academic Emergency Medicine 8(2):117-124, Wiley, United States (2001). [cited by applicant]
Neumar, R.W., et al., “Part 8: Adult advanced cardiovascular life support,” Circulation (2010) 122, suppl. 3, S729-S767. [cited by applicant]
Patel, A., “Is Sotalol more effective than standard beta-blockers for prophylaxis of atrial fibrillation during cardiac surgery?” Interactive CardioVascular and Thoracic Surgery 4 (2005) 147-50. [cited by applicant]
Peters, F.P.J., “Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide,” Netherlands J. of Medicine 53:93-96, Elsevier Science B.B., Netherlands (1998). [cited by applicant]
Peters, N.S., “Post-cardioversion atrial fibrillation: the synthesis of modern concepts?” european Heart J. (2000) 21, 1119-1121. [cited by applicant]
Procainamide Dosage. Drugs.com. Last updated Sep. 13, 2021. 3 pages. [cited by applicant]
Radford, D.J., “Atrial Fibrillation in Children,” Pediatrics 59(2):250-256, Amer. Acad. of Pediatrics, US (1977). [cited by applicant]
Rasmussen, H.S. et al., Dofetilide, A Novel Class III Antiarrhythmic Agent, J Cardiovasc Pharmacol. 1992;20 Suppl 2:S96-105. [cited by applicant]
Rosseau, M. F., Cardiac and Hemodynamic Effects of Intravenous Dofetilide in Patients With Heart Failure, Am J Cardiol 2001;87:1250-1254. [cited by applicant]
Sanjuan, R., “Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery,” Ann Thorac Surg (2004) 77:838-43. [cited by applicant]
Saul, J.P., “Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia,” Clinical Pharma & Therapeutics 69(3): 145-157 (2001). [cited by applicant]
Sedgwick, M. et al., Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug, Br. J. Clin. Pharmac. (1991), 31, 515-519. [cited by applicant]
Snider, M., et al., “Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review,” Clinical Therapeutics vol. 31(36) (2009) 1209-1218. [cited by applicant]
Somberg, et al., “Sotalol versus Amiodarone in Treatment of Atrial Fibrillation,” J. Atrial Fibrillation, Feb.-Mar. 2016, vol. Issue 5. [cited by applicant]
Somberg, J.C., “Gender differences in cardiac repolarization following intravenous sotalol administration,” J. Cardiovascular Pharmacology and Therapeutics (2012) 17(1) 86-92. [cited by applicant]
Somberg, J.C., “QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol,” Cardiology (2010) 116(3):219-25. [cited by applicant]
Somberg, J.C., et al., “Developing a safe intravenous sotalol dosing regimen,” Amer. J. of Therapeutics 17(2010) 365-372. [cited by applicant]
Somberg, John et al. Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion. Cardiol Res. 2020; 11(5):294-304. [cited by applicant]
Sundquist, H.K. et al., “Serum levels and half-life of sotalol in chronic renal failure”, Annals of Clinical Research, Dec. 1, 1975, 7(6), Abstract Only. [cited by applicant]
Thomas, S.P., “Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: A randomized, digoxin-controlled trial,” Am. Heart J., 147(1) (6 pages) (2004). [cited by applicant]
Tse, H.F., “Atrial pacing for suppression of early reinitiation of atrial fibrillation after successful internal cardioversion,” european Heart J. (2000) 21, 1167-1176. [cited by applicant]
U.S. Appl. No. 16/376,706 (U.S. Pat. No. 10,799,138), file history Dec. 2020, 151 pages. [cited by applicant]
Valdes, S.O., “Early experience with intravenous sotalol in children with and without congenital heart disease,” Heart Rhythm 15(12): 1862-1869, Elsevier Inc., (Jul. 9, 2018). [cited by applicant]
Yarlagadda, B, et al., “Safety and efficacy of inpatient initiation of dofetilide versus sotalol for atrial fibrillation,” J. Atrial Fibrillation vol. 101(4) (2017) 1-5. [cited by applicant]
Co-pending U.S. Appl. No. 16/376,706, Final Office Action dated Mar. 27, 2020, 12 pages. [cited by applicant]
Co-pending U.S. Appl. No. 16/376,706, Non-final Office Action dated Nov. 12, 2019, 12 pages. [cited by applicant]
Co-pending U.S. Appl. No. 16/376,706, Notice of Allowance and Examiner Initiated Interview Summary dated Jun. 10, 2020, 8 pages. [cited by applicant]
Co-pending U.S. Appl. No. 16/376,706, Response to Mar. 27, 2020 Final Office Action dated May 27, 2020, 11 pages. [cited by applicant]
Co-pending U.S. Appl. No. 16/376,706, Response to Nov. 12, 2019 Non-Final Office Action filed Feb. 12, 2020, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Final Office Action dated Sep. 3, 2021, 20 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Non-Final Office Action dated Feb. 7, 2020, 12 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Non-Final Office Action dated Jul. 21, 2022, 16 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Notice of Allowance dated Mar. 9, 2023, 7 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Petition Decision dated Mar. 29, 2021, 2 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Response to Feb. 7, 2020 Non-Final Office Action, filed May 5, 2020, 20 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Response to Jul. 21, 2022 Non-Final Office Action including Rule 132 Affidavit, dated Jan. 20, 2023, 15 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,310, Response to Sep. 3, 2021 Final Office Action, dated Feb. 3, 2022, 7 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Final Office Action dated Mar. 29, 2021, 14 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Final Office Action dated Oct. 14, 2022, 16 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Non-Final Office Action dated Jan. 7, 2022, 15 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Non-Final Office Action dated Nov. 1, 2023, 18 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Non-Final Office Action dated Oct. 20, 2020, 17 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Jan. 7, 2022 Non-Final Office Action, dated Jul. 6, 2022, 8 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Mar. 29, 2021 Final Office Action, filed Sep. 29, 2021, 13 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Oct. 14, 2022 Final Office Action dated Apr. 14, 2023, 16 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/693,312, Response to Oct. 20, 2020 Non-Final Office Action, filed Feb. 22, 2021, 11 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/849,099, Final Office Action dated Feb. 3, 2021, 24 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/849,099, Non-Final Office Action dated Jul. 9, 2020, 19 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/849,099, Notice of Abandonment, Aug. 20, 2021, 2 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/849,099, Response to Jul. 9, 2020 Non-Final Office Action, dated Dec. 9, 2020, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Advisory Action dated Dec. 30, 2021, 11 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Final Office Action dated Dec. 28, 2020, 17 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Final Office Action dated Oct. 26, 2021, 11 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Non-Final Office Action and Examiner Initiated Interview Summary dated Jun. 9, 2021, 14 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Non-Final Office Action dated Jun. 4, 2020, 18 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Response to Jun. 4, 2020 Non-Final Office Action dated Dec. 4, 2020, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Response to Jun. 9, 2021 Non-Final Office Action dated Oct. 12, 2021, 8 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Response to May 13, 2020 Restriction Requirement, filed May 26, 2020, 44 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Response to Oct. 26, 2021 Final Office Action, dated Dec. 10, 2021, 8 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/863,567, Restriction Requirement dated May 13, 2020, 5 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/946,941, Non-Final Office Action dated Feb. 7, 2022, 15 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/946,941, Notice of Allowance dated Apr. 4, 2022, 9 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/946,941, Preliminary Amendment filed Jan. 20, 2021, 3 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 16/946,941, Response to Feb. 7, 2022 Non-Final Office Action, dated Mar. 8, 2022, 6 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/306,490, Preliminary Amendment filed Dec. 7, 2022, 38 pages. [cited by applicant]
Co-pending U.S. Appl. No. 17/566,840, Non-Final Office Action dated Mar. 23, 2022, 11 pages. [cited by applicant]
Co-pending U.S. Appl. No. 17/566,840, Notice of Allowance dated Jul. 25, 2022, 7 pages. [cited by applicant]
Co-pending U.S. Appl. No. 17/566,840, Notice of Allowance dated Nov. 9, 2022, 7 pages. [cited by applicant]
Co-pending U.S. Appl. No. 17/566,840, Petition Under 37 CFR 1.181 and Preliminary Amendment, dated Feb. 22, 2022, 9 pages. [cited by applicant]
Co-pending U.S. Appl. No. 17/566,840, Response to Mar. 23, 2022 Non-Final Office Action, dated Jul. 7, 2022, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/585,190, Preliminary Amendment dated Mar. 4, 2022, 4 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/585,190, Restriction Requirement dated Oct. 19, 2023, 5 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 17/861,226, Preliminary Amendment dated Jul. 10, 2022, 4 pages. [cited by applicant]
Dahmane, E., “Clinical Pharmacology-Driven Research to Optimize Bedside Therapeutics of Sotalol Therapy,” Clin Transl Sci (2019) 12:648-656. [cited by applicant]
Co-pending U.S. Appl. No. 18/107,785, Response to May 8, 2025 Non-Final Office Action dated Aug. 1, 2025, 14 pages. [cited by applicant]
Co-pending U.S. Appl. No. 18/107,785, Response to Nov. 5, 2025 Non-Final Office Action dated May 5, 2026, 6 pages. [cited by applicant]
Co-pending U.S. Appl. No. 18/121,980, Non-Final Rejection dated Oct. 22, 2025, 10 pages. [cited by applicant]
Co-pending U.S. Appl. No. 18/121,980, Notice of Allowance dated May 7, 2026, 8 pages. [cited by applicant]
Co-pending U.S. Appl. No. 18/121,980, Preliminary Amendment dated Jul. 18, 2023, 6 pages. [cited by applicant]
Co-pending U.S. Appl. No. 18/121,980, Response to Oct. 22, 2025 Non-Final Rejection dated Apr. 22, 2026, 7 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/126,561, Non-Final Office Action dated Oct. 23, 2025, 26 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/126,561, Response to Oct. 23, 2025 Non-Final Office Action, dated Mar. 23, 2026, 15 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/135,467, Non-Final Office Action dated Nov. 18, 2025, 26 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/135,467, Notice of Allowance dated Apr. 21, 2026, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/135,467, Response to Nov. 18, 2025 Non-Final Office Action, dated Feb. 16, 2026, 7 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/304,196, Restriction Requirement dated Dec. 3, 2025, 6 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/306,660, Non-Final Office Action dated Apr. 10, 2026, 21 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/315,790, Non-Final Office Action dated Apr. 29, 2026, 18 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/321,220, Non-Final Office Action dated May 4, 2026, 22 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/323,337, Non-Final Office Action dated Nov. 3, 2025, 19 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/323,337, Preliminary Amendment dated Oct. 24, 2025, 8 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/323,337, Response to Nov. 3, 2025 Non-Final Office Action, dated May 4, 2026, 10 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/324,703, Non-Final Office Action dated Oct. 17, 2025, 21 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/417,748, Non-Final Office Action dated Oct. 27, 2025, 19 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/417,748, Preliminary Amendment dated Apr. 22, 2024, 6 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/417,748, Response to Oct. 27, 2025 Non-Final Office Action, dated Apr. 27, 2026, 21 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 18/417,748, Second Preliminary Amendment dated Oct. 16, 2025, 4 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 19/019,556, Preliminary Amendment dated Jan. 14, 2025, 4 pages. [cited by applicant]
Co-Pending U.S. Appl. No. 19/292,715, Preliminary Amendment filed Oct. 23, 2025, 6 pages. [cited by applicant]
Dailymed Website, Tikosyn (dofetilide) Capsules, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=02438044-d6a3-49e9-a1ac-3aad21ef2c8c (Year: 1999), 21 pages. [cited by applicant]
Dwivedi, S.K. et al. “Efficacy of Dual Strategy of Sotalol and Electrical Cardioversion With Balloon Mitral Valvotomy in Persistent Rheumatic Atrial Fibrillation With Mitral Stenosis,” Heart, 2012, 98 (Suppl 2): E1-E319… [cited by applicant]
Falk, Rodney H. et al., Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter, JACC vol. 29, No. 2, 385-90 (Feb. 1997). [cited by applicant]
Frost, L. et al., Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery, International Journal of Cardiology… [cited by applicant]
Kennedy, D. et al. “Efficacy and Safety of Single Day Loading of Intravenous Sotalol Prior to Direct Current Cardioversion for the Termination of Cardiac Atrial Arrhythmias: An Observational Study,” Heart Rhythm, vol. 1… [cited by applicant]
Kerin, N. Z. and Jacob, S., The Efficacy of Sotalol in Preventing Postoperative Atrial Fibrillation: A Meta-Analysis, The American Journal of Medicine, vol. 124, No. 9, Sep. 2011, 9 pages. [cited by applicant]
Kijtawornrat, A. et al., Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts, The Journal of Toxicological Sciences, 2012, vol. 37, No. 3, 455-462. [cited by applicant]
Kobayashi, Y. et al. “Clinical and Electrophysiologic Effects of Dofetilide in Patients with Supraventricular Tachyarrhythmias”, Journal of Cardiovascular Pharmacology, Sep. 1997, vol. 30, Issue 3, 367-373, 9 pages. [cited by applicant]
Lai, L. et al. “Intravenous Sotalol Decreases Transthoracic Cardioversion Energy Requirement for Chronic Atrial Fibrillation in Humans: Assessment of the Electrophysiological Effects by Biatrial Basket Electrodes,” Jour… [cited by applicant]
Levy, A. et al., “Applications of machine learning in decision analysis for dose management for dofetilide”, PLoS ONE 14(12): e0227324, Dec. 2019, 13 pages. [cited by applicant]
Lindeboom, J. et al. Efficacy and Safety of Intravenous Dofetilide for Rapid Termination of Atrial Fibrillation and Atrial Flutter, The American Journal of Cardiology, vol. 85, Apr. 15, 2000, 1031-1033, 3 pages. [cited by applicant]
Malloy-Walton, L. E. et al. “IV Sotalol Use in Pediatric and Congenital Heart Patients: A Multicenter Registry Study,” Journal of the American Heart Association, 2022, 11:e024375, 8 pages. [cited by applicant]
Norgaard, B. et al., Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial, American Hear… [cited by applicant]
Pool et al. “Effects of Intravenous Dofetilide in Patients with Frequent Premature Ventricular Contractions: A Clinical Trial”; Clin. Cardiol. 23, 415-416 (2000). [cited by applicant]
Prystowsky, E. et al., “Clinical Experience with Dofetilide in the Treatment of Patients with Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology, vol. 14, No. 12, Supplement, Dec. 2003, S287-S290. [cited by applicant]
Singh, Steven et al., Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigativ… [cited by applicant]